Tracking pancreas function in people with pancreatic cysts
Part of Digestive system clinical trials.
This study looks at people with a type of pancreatic cyst called an IPMN. Doctors want to see if measuring how well your pancreas makes digestive enzymes can help predict how the cyst will progress. Taking part may help tailor your monitoring and catch problems earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have a pancreatic cyst called an IPMN (intraductal papillary mucinous neoplasm) — either the branch duct, main duct, or mixed type.
- You are regularly monitored with imaging scans (like MRI or CT) to watch the cyst.
- You have not had surgery on your pancreas.
- You do not have long-term pancreatitis or other known causes of poor pancreas function unrelated to your cyst.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from people who have an IPMN cyst in the pancreas to help predict who may be at higher risk of pancreatic cancer. It may help your care team estimate risk and plan follow-up more effectively.
This study looks for “biomarkers,” meaning measurable signs in the blood, in people diagnosed with intraductal papillary mucinous neoplasm (IPMN). It aims to better understand what changes happen in this condition and may help future diagnosis or monitoring.
This study follows people with small, low-risk pancreatic cysts to see if they can be safely monitored without surgery. It aims to confirm that watching these cysts closely is a good alternative to immediate treatment.
This study looks at using MRI scans to find pancreatic cancer early in people who have certain types of pancreatic cysts that may raise their risk. If you have these cysts, joining could help catch any cancer sooner, when it might be easier to treat.
This trial studies whether blood markers can help predict which pancreatic IPMNs are likely to become cancerous. If successful, it could help doctors decide when surgery is needed.
This study looks at how GLP-1 receptor agonist medicines (commonly used for diabetes or weight loss) affect a type of pancreatic cyst called IPMN. If you have IPMN and take this type of medicine, your data may help doctors understand whether it changes the cyst's behavior.
Hear when a new Intraductal Papillary Mucinous Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.